HUTCHMED (China) vs Zai Lab
HCM and ZLAB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HCM and ZLAB compare
Zai Lab grew revenue faster over the last twelve months (0.02% versus −13.0% for HUTCHMED (China)).
HUTCHMED (China) keeps more of each dollar of sales as profit, with a net margin of 83.3% compared with −44.9% at Zai Lab.
Zai Lab scores higher on the StockData Score (6 against 5 for HUTCHMED (China)), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HCM | ZLAB |
|---|---|---|
| Size and price | ||
| Market cap | – | $38.2B |
| Share price | $14.90 | $24.60 |
| Change, 1 year | −2.5% | 12.4% |
| Change, 5 years | −51.5% | −70.8% |
| Beta (5Y) | 0.97 | 1.10 |
| Employees | 109 | 1,784 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 3 | 3 |
| Health score | 2 | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 86.5× |
| P/B | – | 67.8× |
| FCF yield | – | −0.43% |
| Fair value | – | $4.31 |
| Margin of safety | – | −471% |
| Growth | ||
| Revenue growth (TTM) | −13.0% | 0.02% (better) |
| Revenue growth, 5Y average | 19.2% | 56.5% (better) |
| Net income growth (TTM) | 1111% | – |
| EPS growth (TTM) | 1200% | – |
| Profitability | ||
| Gross margin | 38.7% | 54.7% (better) |
| Operating margin | −7.1% (better) | −63.0% |
| Net margin | 83.3% (better) | −44.9% |
| FCF margin | −14.4% (better) | −37.0% |
| Return on equity | 36.7% (better) | −30.0% |
| Return on invested capital | – | −87.6% |
| Financial health | ||
| Debt / equity | 0.09 (better) | 0.45 |
| Interest coverage | −13.7× (better) | −45.2× |
| Current ratio | 5.64 (better) | 2.04 |
| Altman Z-score | – | 46.02 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.51% | 2.8% |
| Held by insiders | 0.44% | 0.67% |
| Insider net buying, 12 months | – | −$10.8M |
Go deeper
- HCM stock overview
- HCM income statement
- HCM valuation and score
- ZLAB stock overview
- ZLAB income statement
- ZLAB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.